Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy
Yoshiki Takai(Fukushima Medical University), Masashi Aoki(Tohoku University), Shuhei Nishiyama(Fukushima Medical University), Toshiyuki Takahashi(Fukushima Medical University), Tetsuya Akaishi(Tohoku University Hospital), Kazuo Fujihara(Tohoku University), Hiroshi Kuroda(Fukushima Medical University), Ichiro Nakashima(Tohoku University), Tatsuro Misu(Fukushima Medical University)
Cited by 43
Related Papers
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
|The Lancet|2004|3.2k
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
|Neurology Neuroimmunology & Neuroinflammation|2017|432
CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
|Journal of Neurology Neurosurgery & Psychiatry|2018|199
MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study: Table 1
|Journal of Neurology Neurosurgery & Psychiatry|2015|141
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies
|Journal of Neurology Neurosurgery & Psychiatry|2016|108